Kin Fen Kevin Fung, Philippe Barthelemy, Fabien Moinard-Butot, Mathilde Airoldi, Roberto Luigi Cazzato, Afshin Gangi
{"title":"超越手术刀:免疫治疗时代图像引导热消融在转移性肾细胞癌治疗中的作用。","authors":"Kin Fen Kevin Fung, Philippe Barthelemy, Fabien Moinard-Butot, Mathilde Airoldi, Roberto Luigi Cazzato, Afshin Gangi","doi":"10.1007/s00270-025-04101-y","DOIUrl":null,"url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is the most common type of kidney cancer and accounts for approximately 90% of all renal malignancies. About 30% of patients have metastatic disease at their initial presentation. Historically, these patients have very poor prognosis with a median survival of 12 months. The recent introduction of immune checkpoint inhibitors (ICI)-based immunotherapy, which disrupts cancer-induced immune tolerance and promotes immune-mediated cancer cell killing, has significantly improved patient outcome. While ICI-based therapy represents the standard of care for metastatic RCC, there are significant treatment-related adverse effects. This review article will examine how image-guided ablation, as an adjunct to immunotherapy, can improve survival and quality of life in patients with metastatic RCC.</p>","PeriodicalId":9591,"journal":{"name":"CardioVascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Beyond the Scalpel: the Role of Image-Guided Thermal Ablation in Management of Metastatic Renal Cell Carcinoma in the Era of Immunotherapy.\",\"authors\":\"Kin Fen Kevin Fung, Philippe Barthelemy, Fabien Moinard-Butot, Mathilde Airoldi, Roberto Luigi Cazzato, Afshin Gangi\",\"doi\":\"10.1007/s00270-025-04101-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Renal cell carcinoma (RCC) is the most common type of kidney cancer and accounts for approximately 90% of all renal malignancies. About 30% of patients have metastatic disease at their initial presentation. Historically, these patients have very poor prognosis with a median survival of 12 months. The recent introduction of immune checkpoint inhibitors (ICI)-based immunotherapy, which disrupts cancer-induced immune tolerance and promotes immune-mediated cancer cell killing, has significantly improved patient outcome. While ICI-based therapy represents the standard of care for metastatic RCC, there are significant treatment-related adverse effects. This review article will examine how image-guided ablation, as an adjunct to immunotherapy, can improve survival and quality of life in patients with metastatic RCC.</p>\",\"PeriodicalId\":9591,\"journal\":{\"name\":\"CardioVascular and Interventional Radiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CardioVascular and Interventional Radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00270-025-04101-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CardioVascular and Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00270-025-04101-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Beyond the Scalpel: the Role of Image-Guided Thermal Ablation in Management of Metastatic Renal Cell Carcinoma in the Era of Immunotherapy.
Renal cell carcinoma (RCC) is the most common type of kidney cancer and accounts for approximately 90% of all renal malignancies. About 30% of patients have metastatic disease at their initial presentation. Historically, these patients have very poor prognosis with a median survival of 12 months. The recent introduction of immune checkpoint inhibitors (ICI)-based immunotherapy, which disrupts cancer-induced immune tolerance and promotes immune-mediated cancer cell killing, has significantly improved patient outcome. While ICI-based therapy represents the standard of care for metastatic RCC, there are significant treatment-related adverse effects. This review article will examine how image-guided ablation, as an adjunct to immunotherapy, can improve survival and quality of life in patients with metastatic RCC.
期刊介绍:
CardioVascular and Interventional Radiology (CVIR) is the official journal of the Cardiovascular and Interventional Radiological Society of Europe, and is also the official organ of a number of additional distinguished national and international interventional radiological societies. CVIR publishes double blinded peer-reviewed original research work including clinical and laboratory investigations, technical notes, case reports, works in progress, and letters to the editor, as well as review articles, pictorial essays, editorials, and special invited submissions in the field of vascular and interventional radiology. Beside the communication of the latest research results in this field, it is also the aim of CVIR to support continuous medical education. Articles that are accepted for publication are done so with the understanding that they, or their substantive contents, have not been and will not be submitted to any other publication.